• Explore /
  • Poster
  • / A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.

A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.

Abstract Poster

Authors

Daniel Castellano

Daniel E. Castellano

Hospital 12 de Octubre, Madrid, Spain

Daniel E. Castellano , Miguel A. Climent , Ignacio Duran , Begona Mellado , Jesus Paramio , Francisco X. Real , Jose Luis Ramirez , Juan Luis Sanz , Albert Font Pous

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03425201

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4593)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4593

Abstract #

TPS4593

Poster Bd #

415b

Abstract Disclosures

Similar Posters

First Author: Albert Font Pous

First Author: Daniel E. Castellano

First Author: Marcia Hall

First Author: Abhishek Tripathi